Immunovant
320 West 37th Street
New York
NY
10018
United States
Tel: 9145222605
22 articles with Immunovant
-
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended December 31, 2022
2/3/2023
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today reported recent company updates and financial results for its fiscal third quarter ended December 31, 2022.
-
Immunovant to Present at Guggenheim 4th Annual Immunology and Neurology Day on November 14th
11/7/2022
Immunovant, Inc. today announced that Pete Salzmann, M.D., chief executive officer, will participate in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Day, taking place November 14th -15th , 2022.
-
Immunovant Reports Financial Results and Recent Business Updates for the Quarter Ended September 30, 2022
11/4/2022
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today reported recent company updates and financial results for its fiscal second quarter ended September 30, 2022.
-
Immunovant Announces Pricing of $75.0 Million Underwritten Offering of Common Stock
10/4/2022
Immunovant, Inc., a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at an offering price of $6.00 per share.
-
Immunovant Announces IMVT-1402, a Next Generation Anti-FcRn
9/28/2022
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced a new anti-FcRn, IMVT-1402, at Roivant’s Investor Day at 11:00am on September 28, 2022.
-
Immunovant to Present at Roivant Investor Day on September 28th
9/21/2022
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will present a corporate update at Roivant’s Investor Day, taking place on September 28th, 2022.
-
Immunovant to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14th
9/9/2022
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company committed to enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference, taking place September 12th-14th, 2022.
-
Immunovant Announces Two New Development Programs for Batoclimab
9/7/2022
“We are excited to announce the addition of two new target indications for batoclimab, one of which will be a pivotal program, confirming our confidence in the broad development opportunity for batoclimab,” said Pete Salzmann, M.D., Chief Executive Officer of Immunovant.
-
Immunovant to Host Investor Webcast to Announce Two New Indications for Batoclimab on September 7, 2022
8/24/2022
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, will host a webcast for the investment community to announce two new indications for batoclimab on Wednesday, September 7, 2022 at 8:00 AM ET.
-
Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022
6/8/2022
Immunovant, Inc. announced that it has achieved alignment with the United States Food and Drug Administration Division of Ophthalmology on plans to initiate two placebo-controlled Phase 3 clinical trials to evaluate batoclimab in TED.
-
Immunovant to Report Fourth Quarter and Full Year 2022 Financial Results on June 8, 2022
6/6/2022
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it will report its fourth quarter and full-year 2022 financial results before the open of the U.S. financial markets on Wednesday, June 8, 2022.
-
Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th
5/23/2022
Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference.
-
Immunovant to Present at the UBS Global Healthcare Conference on May 23rd
5/19/2022
Immunovant, Inc. announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the UBS Global Healthcare Conference, taking place May 23rd-25th, 2022.
-
Immunovant to Present at LifeSci Partners’ Immunology and Inflammation Symposium on May 10th
5/4/2022
Immunovant, Inc. today announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at LifeSci Partners’ virtual Immunology and Inflammation Symposium, taking place May 10th -11th , 2022.
-
Immunovant to Host Virtual R&D Day on March 30, 2022
3/28/2022
Immunovant, Inc. today announced that it will host a virtual R&D event on Wednesday, March 30, 2022, from 9:00 AM ET to 11:00 AM ET.
-
Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference
2/9/2022
Immunovant, Inc., a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced that Pete Salzmann, M.D., Chief Executive Officer, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference, taking place February 14 - 18, 2022.
-
Immunovant Reports Financial Results for the Quarter Ended December 31, 2021Company Ended the Quarter With Cash of Approximately $527.0 Million
2/4/2022
Immunovant, Inc. today reported financial results for its fiscal first quarter ended December 31, 2021.
-
Immunovant Appoints Mark Levine as Chief Legal Officer
1/25/2022
Immunovant, Inc announced the appointment of Mark Levine as Chief Legal Officer.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/7/2022
Immunovant, Inc. today announced that Pete Salzmann, M.D., Chief Executive Officer, will provide a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference, taking place January 10 - 13, 2022.